• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Caribou Biosciences Inc.

    4/30/25 10:58:09 AM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRBU alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Caribou Biosciences Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    142038108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    142038108


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    35,754.00
    7Sole Dispositive Power

    4,457,177.00
    8Shared Dispositive Power

    64,855.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,522,032.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.86 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Caribou Biosciences Inc
    (b)Address of issuer's principal executive offices:

    2929 7th Street, Suite 105, Berkeley, CA, 94710
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    142038108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4522032
    (b)Percent of class:

    4.86  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    35754

     (iii) Sole power to dispose or to direct the disposition of:

    4457177

     (iv) Shared power to dispose or to direct the disposition of:

    64855

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:04/30/2025
    Get the next $CRBU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRBU

    DatePrice TargetRatingAnalyst
    6/3/2024$13.00 → $3.00Outperform → In-line
    Evercore ISI
    11/8/2023Neutral
    Cantor Fitzgerald
    10/31/2023$13.00Outperform
    Evercore ISI
    7/11/2023$23.00Buy
    Truist
    2/18/2022$22.00Outperform
    RBC Capital
    2/14/2022$19.00Buy
    Brookline Capital
    12/1/2021$36.00Outperform
    Oppenheimer
    11/30/2021$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $CRBU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

      BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transforma

      5/28/25 4:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

      -- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company's current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and provided a business update for its lead oncology clinical programs CB-010 and CB-011 with data disclosure for each planned for H2 2025. "Caribou's two lead Phase 1 clinical programs, CB-010 for large B cell lymphoma and CB-011 for

      5/8/25 4:05:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

      BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing trans

      5/6/25 4:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Caribou Biosciences downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Caribou Biosciences from Outperform to In-line and set a new price target of $3.00 from $13.00 previously

      6/3/24 7:23:52 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Caribou Biosciences

      Cantor Fitzgerald initiated coverage of Caribou Biosciences with a rating of Neutral

      11/8/23 7:19:33 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Caribou Biosciences with a new price target

      Evercore ISI initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $13.00

      10/31/23 8:58:42 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Haurwitz Rachel E. bought $20,400 worth of shares (20,000 units at $1.02) (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      3/17/25 8:01:22 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Ryali Sriram bought $24,651 worth of shares (17,360 units at $1.42) (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      1/30/25 4:02:12 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Haurwitz Rachel E. bought $20,400 worth of shares (20,000 units at $1.02) (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      3/17/25 8:01:22 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Haurwitz Rachel E. was granted 136,750 shares, increasing direct ownership by 86% to 295,450 units (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      2/21/25 8:21:07 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Albertson Tina M. was granted 14,589 shares (SEC Form 4)

      4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

      2/21/25 8:20:34 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    SEC Filings

    See more
    • Caribou Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

      6/13/25 4:02:09 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Caribou Biosciences Inc.

      EFFECT - Caribou Biosciences, Inc. (0001619856) (Filer)

      5/15/25 12:15:15 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Caribou Biosciences Inc.

      DEFA14A - Caribou Biosciences, Inc. (0001619856) (Filer)

      5/8/25 5:05:27 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Leadership Updates

    Live Leadership Updates

    See more
    • Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

      BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communications functions. He will report to Rachel Haurwitz, PhD, Caribou's president and chief executive officer. "I am excited to welcome Sri to Caribou at the beginning of this pivotal year for our organiz

      1/2/25 8:00:00 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

      -- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin

      8/12/24 8:00:00 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

      -- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med

      7/9/24 8:00:00 AM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Financials

    Live finance-specific insights

    See more
    • Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

      -- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved outcomes in partially HLA matched cohort -- -- Off-the-shelf CB-010 is partially HLA matched to patient within current screening timelines -- -- KOL webcast discussion of data from 46

      6/2/24 7:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

      -- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases -- -- Advancing ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be shared at a medical congress in Q2 2024 -- -- Conference call and webcast scheduled for today at 5:00 pm ET -- BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, t

      4/4/24 4:00:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

      -- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is the longest CR maintained to date -- -- LBCL patient subgroup had a 50% CR rate at ≥6 months; 18 months is the longest LBCL subgroup CR maintained to date -- -- Actively enrolling second-line LBCL patients in ANTLER dose expansion -- -- Conference call and webcast scheduled for today at 4:30 pm ET -- BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-s

      7/13/23 4:01:00 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRBU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Caribou Biosciences Inc.

      SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)

      12/6/24 4:06:56 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

      SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

      11/14/24 7:53:54 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

      SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

      11/14/24 6:08:51 PM ET
      $CRBU
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care